Artelo Biosciences (NASDAQ:ARTL) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Zacks has also given Artelo Biosciences an industry rank of 69 out of 256 based on the ratings given to related companies.

Separately, Maxim Group reaffirmed a “buy” rating and set a $22.50 target price (up previously from $4.50) on shares of LendingClub in a report on Tuesday, July 9th.

ARTL traded down $0.30 during midday trading on Thursday, reaching $3.39. 42,730 shares of the company’s stock were exchanged, compared to its average volume of 19,037. Artelo Biosciences has a one year low of $1.62 and a one year high of $10.50.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia.

Featured Story: The basics of gap trading strategies

Get a free copy of the Zacks research report on Artelo Biosciences (ARTL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with's FREE daily email newsletter.